Stem cell biology is scientifically, clinically, and politically a current topic. The hematopoietic stem cell, the common ancestor of all types of blood cells, is one of the best-characterized stem cells in the body and the only stem cell that is clinically applied in the treatment of diseases such as breast cancer, leukemias, and congenital immunodeficiencies. Multicolor cell sorting enables the purification not only of hematopoietic stem cells, but also of their downstream progenitors such as common lymphoid progenitors and common myeloid progenitors. Recent genetic approaches including gene chip technology have been used to elucidate the gene expression profile of hematopoietic stem cells and other progenitors. Although the mechanisms that control self-renewal and lineage commitment of hematopoietic stem cells are still ambiguous, recent rapid advances in understanding the biological nature of hematopoietic stem and progenitor cells have broadened the potential application of these cells in the treatment of diseases.

Graft-versus-host disease (GVHD) is a major obstacle in allogeneic hematopoietic cell transplantation. Given the dynamic changes in immune cell subsets and tissue organization, which occur in GVHD, localization and timing of critical immunological events in vivo may reveal basic pathogenic mechanisms. To this end, we transplanted luciferase-labeled allogeneic splenocytes and monitored tissue distribution by in vivo bioluminescence imaging. High-resolution analyses showed initial proliferation of donor CD4 ؉ T cells followed by CD8 ؉ T cells in secondary lymphoid organs with subsequent homing to the intestines, liver, and skin. Transplantation of purified naive T cells caused GVHD that was initiated in secondary lymphoid organs followed by target organ manifestation in gut, liver, and skin. IntroductionAllogeneic hematopoietic cell transplantation (HCT) has proven to be an effective therapy for a variety of life-threatening malignancies. 1 The beneficial effects of HCT are due to the graft-versustumor reaction, which is capable of destroying residual tumor cells that persist after chemotherapy or radiation therapy. 2 However, allogeneic HCT is limited by the immunologic recognition and destruction of host tissues, termed graft-versus-host disease (GVHD). Acute GVHD continues to be a major source of morbidity and mortality following HCT, which limits treatment of a broader spectrum of diseases, such as autoimmune diseases or organ transplant rejection. 3,4 Tissue-specific destruction of GVHD target organs, as gastrointestinal tract, liver, and skin, underlines the importance of migration capacities of alloreactive T lymphocytes. 5,6 In the current study we aimed to determine the time points of organ infiltration and focused on the role of different lymphoid organs in initiating acute GVHD. We used in vivo bioluminescence imaging (BLI) to analyze the migration pattern of whole splenocytes after transplantation into allogeneic recipients. BLI has already proven to be a sensitive and accurate means of characterizing engraftment patterns of hematopoietic stem cells, of monitoring tumor cell growth, and of assessing response to conventional and biological therapies. [7][8][9] We also aimed to clarify the role of different T-cell subsets during GVHD development. It is reported in the literature [10][11][12] that CD4 ϩ effector memory T (T EM ) cells do not cause GVHD. This prompted us to characterize their trafficking and proliferation pattern in vivo, while comparing it to purified naive CD4 ϩ T lymphocytes. Materials and methods MiceFVB/N (H-2 q , Thy1.1) mice and Balb/c mice (H-2 d , Thy1.2) were purchased from Jackson Laboratory (Bar Harbor, ME). The luciferaseexpressing (luc ϩ ) transgenic FVB/N line was generated as previously described. 9 Female heterozygous luc ϩ offspring of the transgenic founder line FVB-L2G85 were used for all transplantation experiments. All animal studies were performed under institutional approval. Flow cytometric cell purification and analysisThe following antibodies were purchased from...

Purified hematopoietic stem cells (HSCs) were transplanted into NOD mice to test whether development of hyperglycemia could be prevented. Engraftment of major histocompatibility complex-mismatched HSCs was compared with bone marrow (BM) grafts. HSCs differed from BM because HSCs were more strongly resisted and HSC recipients retained significant levels of NOD Tcells, whereas BM recipients were full donor chimeras. Despite persistent NOD T-cells, all HSC chimeras were protected from hyperglycemia, and attenuation of islet lesions was observed. T-cell selection was altered in allogeneic HSC recipients as demonstrated by deletion of both donor and host superantigen-specific T-cells. Syngeneic and congenic hematopoietic cell transplants were also performed to differentiate the influence of the preparative regimen(s) versus the allografts. Unlike the allogeneic HSC transplantations, syngeneic or congenic grafts did not retard diabetes development. In a pilot study, overtly diabetic NOD mice were cured by cotransplantation of allogeneic HSCs and donor-matched islets. We conclude that allogeneic HSC transplants block allo-and autoimmunity, despite residual host T-cell presence. These data demonstrate for the first time that purified HSC grafts block development of autoimmune diabetes and illuminate how HSC grafts alter thymic and peripheral T-cell responses against auto-and alloantigens. Diabetes 52:59 -68, 2003

In acute graft-versus-host disease (aGVHD), donor T cells attack the recipient's gastrointestinal tract, liver, and skin. We hypothesized that blocking access to distinct lymphoid priming sites may alter the specific organ tropism and prevent aGVHD development. In support of this initial hypothesis, we found that different secondary lymphoid organs (